ATAP Inclusion/Exclusion and List of Study Sites
Posted on: December 07, 2009
This information was complied from the information provided on clinicaltrials.gov.
To read, please download file by clicking here.
The Official Website of the Acid Maltase Deficiency Association
It is difficult to say what is impossible for the dreams of yesterday are the hopes of today and the reality of tomorrow. - Robert H. Goddard
Get Involved
Your generous contribution will go a long way into improving the quality of life of Pompe Disease Patients worldwide. Donations go towards Pompe Disease Research.
Recently Added Items
- 2019 AMDA/IPA International Conference was posted in Patient Conferences, last February 17, 2019
- 2019 PCMA’s Pull For Pompe! was posted in News, last January 23, 2019
- Systemic Delivery of AAVB1-GAA Clears Glycogen and Prolongs Survival in a Mouse Model of Pompe Disea was posted in Publications, last January 10, 2019
- Press Release: Amicus Therapeutics Announces First Patient Dosed in Phase 3 PROPEL Study was posted in News, last December 20, 2018
- The ACE I/D polymorphism does not explain heterogeneity of natural course and response to enzyme rep was posted in Publications, last December 07, 2018
Disclaimer: The AMDA does not endorse any of the products, medications, treatments or information reported herein. The website and its contents is intended for informational purposes, only. We strongly advise that you discuss all medications, treatments, and/or products with your physician.
© 2011 Acid Maltase Deficiency Association
Address: AMDA PO Box 700248
San Antonio, Texas 78270 USA